Lung Cancer
Volume 75, Issue 2 , Pages 146-150 , February 2012

Implementation of hypoxia measurement into lung cancer therapy

  • Xue Meng

      Affiliations

    • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China
    • ,
  • Feng-Ming (Spring) Kong

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, USA
    • ,
  • Jinming Yu

      Affiliations

    • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China
    • Corresponding Author InformationCorresponding author at: No 440, Jiyan Road, Shandong 250117, China. Tel.: +86 531 87984729; fax: +86 531 87984079.

Received 1 July 2011 ,Revised 11 September 2011 ,Accepted 14 September 2011.

References 

  1. Graves EE, Maity A, Le QT. The tumor microenvironment in non-small cell lung cancer. Semin Radiat Oncol. 2010;20:156–163
  2. Mees G, Dierckx R, Vangestel C, et al. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging. 2009;36:1674–1686
  3. Vikram DS, Zwerer JL, Kuppusamy P. Methods for noninvasive imaging of tissue hypoxia. Antioxid Redox Signal. 2007;9:1745–1756
  4. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006;12:1507–1514
  5. Hung JJ, Yang MH, Hsu HS, et al. Prognostic significance of hypoxia-inducible factor-1 α, TWIST 1 and Snail expression in resectable non-small cell lung cancer. Thorax. 2009;12:1082–1089
  6. Llie M, Mazure NM, Hofman V, et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer. 2010;11:1627–1635
  7. Mack Philip C, Redman Mary W, Chansky Kari, et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy: SWOG study S0003. J Clin Oncol. 2008;26:4771–4776
  8. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199–212
  9. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417–428
  10. Cherk MH, Foo SS, Poon AM, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J Nucl Med. 2006;47:1921–1926
  11. Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitromidazole as a PET agent for imaging tumor hypoxia. Radiology. 1995;194:795–800
  12. Hu M, Kong L, Zhao SQ, et al. Value of 18F-FETNIM PET-CT for detection of tumor hypoxia in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi (Chinese). 2010;6:463–466
  13. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18Ffluoroazomycin arabinoside. J Nucl Med. 2005;46:106–113
  14. Reischl G, Dorow DS, Cullinane C, et al. Imaging of hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA—first small animal PET results. J Pharm Pharm Sci. 2007;10:203–211
  15. Postema EJ, McEwan AJ, Riauka TA, et al. Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging. 2009;36:1565–1573
  16. Takahashi N, Fujibayashi Y, Yonekura Y, et al. Evaluation of 62Cu-labeled diacetyl-bis(N 4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med. 2000;14:323–328
  17. Talakad GL, Takashi K, Yoshiki D, et al. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med. 2009;50:1948–1953
  18. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253–260
  19. Gagel B, Reinartz P, Demirel C, et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer. 2006;6:51–57
  20. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391–398
  21. Li L, Hu M, Zhu H, et al. Comparison of 18F-fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small cell lung cancer. Clin Lung Cancer. 2010;5:335–340
  22. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60CU-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844–850
  23. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 1996;6:10–21
  24. Williamson SK, Crowley JJ, Lara PN, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-smallcell lung cancer: Southwest Oncology Group trial S0003. J Clin Oncol. 2005;23:9097–9104
  25. Le QT, McCoy J, Williamson S, et al. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clin Cancer Res. 2004;10:5418–5424
  26. Le QT, Moon J, Redman M, et al. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol. 2009;27:3014–3019
  27. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45:787–795
  28. Koto M, Takai Y, Ogawa Y, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2007;85:429–434
  29. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:1171–1182

PII: S0169-5002(11)00478-8

doi: 10.1016/j.lungcan.2011.09.009

Lung Cancer
Volume 75, Issue 2 , Pages 146-150 , February 2012

Article Tools